Test to play and to stay

When COVID-19 cases began to rise dramatically in Utah in November 2020, schools faced a difficult choice. They could maintain normal activities, giving students valuable in-person instruction and social interaction but risking spread of COVID-19. Or they could send students home, keeping them safe from disease but putting their education, emotional health and social well-being at risk.

With a goal of preserving the best of both worlds, Utah Department of Health (UDOH) implemented two COVID-19 testing programs in collaboration with local health departments and Utah schools. These programs helped students participate in extracurricular activities and stay in school while likely reducing spread of the virus.

“For most students, being able to attend school in-person and participate in extracurricular activities is best for their learning as well as their social and emotional well-being,” says Adam Hersh, senior author on the study, professor of pediatrics at University of Utah Health, and Utah HERO investigator. Hersh collaborated with UDOH to study these testing programs. “When combined with other prevention strategies, most importantly masking, these testing strategies helped keep our schools safe and open.”

Testing allowed for the completion of 95% of more than 11,000 high school extracurricular competition events and saved an estimated 109,752 in-person instruction days for students. The results were published in the Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report (MMWR).

“Before the school year started, our school communities advocated for safe in-person education and participation in extracurricular activities,” says Kendra Babitz, COVID-19 State Testing Coordinator, UDOH. “Their dedication to maintaining optimal environments for learning and growth made these programs a success and kept kids in school.”

One COVID-19 testing program, “Test to Play”, was implemented in 66% (127 of 193) of Utah’s public high schools. In order to participate in extracurricular activities such as sports, students took part in mandatory, rapid antigen testing every 14 days.

“Test to Stay” was presented as an option when schools had outbreaks. Of the 28 high schools that reported outbreaks, 13 elected to conduct school-wide Test to Stay events. Students who tested positive were required to isolate for 10 days while students who tested negative could continue in-person learning.

Between November 30, 2020, and March 20, 2021, schools reported 165,078 tests. Among the 59,552 students tested, 1,886 (3.2%) had a positive result.

The study authors say that by identifying these positive cases, the testing programs likely helped reduce the spread of COVID-19 in schools and the community by enabling the students who tested positive to isolate while their close contacts could quarantine.

“Utah’s high school testing programs could not have been successful without the willingness, flexibility, and innovation of school staff,” said Commander William A. Lanier, lead author of the study and U.S. Public Health Service officer who was assigned to the UDOH to help with COVID-19 testing. “Their hard work helped preserve extracurricular and in-person learning opportunities for Utah students during a very challenging time.”

New partnership to develop a new ultra-fast test for COVID-19 antibodies

Find the original release online: https://pivotcenter.utah.edu/press-release/university-of-utah-arup-and-techcyte-develop-nanospot-ai-a-new-ultra-fast-test-for-covid-19-antibodies/

The University of Utah, ARUP Laboratories, and Techcyte Inc. announced today that they have formed a partnership to develop NanoSpot.AI, a less than five-minute, easy-to-administer SARS-CoV-2 antibody test. NanoSpot.AI is estimated to be significantly less expensive to manufacture than other SARS-CoV-2 antibody tests, so it has the potential to be considerably more affordable than currently available tests, making it possible to extend the test to every corner of the world.

The patent-pending NanoSpot.AI is performed on a spot of blood obtained through a finger prick. Individuals then receive their test results on their mobile phones. The test could be used around the globe to help prioritize who should receive SARS-CoV-2 vaccinations, or to easily and quickly detect whether individuals have some immunity against COVID-19 for travel or immigration purposes. Clinical studies validating NanoSpot.AI are currently underway.

A close up of two people's hands. One person is wearing white rubber gloves pricking an ungloved finger. The testing card is on the table.

The NanoSpot.AI rapid COVID-19 antibody test is performed on blood collected through a finger prick using a microcollection tube. Droplets of blood are then placed on three spots on a ready-to-use, synthetic, embossed card. One of the spots displays the test result, while the other two spots are positive and negative controls for the test.

“Other antibody tests are available and are very good, but it takes time to get test results back and they’re relatively expensive,” said Hans Haecker, MD, PhD, who codeveloped NanoSpot.AI with Vanessa Redecke, MD, PhD. Both are professors in the U Pathology Department Division of Microbiology and Immunology. “Based on what we know so far, we believe NanoSpot.AI checks all the boxes,” Haecker said. “Because it is simple, fast, and very affordable, it can be done anywhere without specialized equipment, creating the potential for us to have an impact on human health around the world.”

The partners in NanoSpot.AI created a video that explains the science behind the assay, demonstrates how the test is administered, and provides details about the AI used to analyze and confirm test results.

“As a national reference laboratory, ARUP has a wide view of laboratory diagnostics,” said Mark Astill, ARUP director of Research and Development. “The expertise and experience we bring enabled what may be the first instance of combining seemingly disparate elements to produce a rapid, economical, QR-code-curated, consistent, point-of-care result.”

All NanoSpot.AI test components are provided in a self-contained kit. The person administering the test places droplets of blood in three small spots on a ready-to-use card. One of the spots displays the test result while the other two confirm the test was properly run. Antibodies against SARS-CoV-2 are quickly apparent because the blood spot begins to separate within seconds when the test result is positive.

To ensure accurate results, the person administering the test uses a mobile phone to take a photograph of the card, which is then transmitted to Techcyte for analysis using the company’s AI-based image analysis tool. Techcyte, a U startup company, is a developer of artificial intelligence (AI)-based image analysis solutions for the diagnostics industry.

A white index-sized card with the nanospot website on the top. The center has three open circles that you smear blood on. The sides have a QRT code.

When blood spots collected for the NanoSpot.AI rapid COVID-19 antibody test are mixed with a predispensed, dried reagent on the test card, the blood spot on the circle displaying the test result shows agglutination that indicates SARS-CoV-2 antibodies are present.

Techcyte CEO Ben Cahoon said the company modified its digital diagnostics platform to work with images captured by mobile phones rather than microscopes for NanoSpot.AI.

“Our platform breaks each blood spot into thousands of features that the AI uses to statistically determine which specimens are positive for SARS-CoV-2 antibodies,” Cahoon said.

Haecker said the assay can be easily adapted to test for antibodies to SARS-CoV-2 variants as new mutations emerge. The test can be viewed as a platform because it and the AI can be developed to test for antibodies against other viruses.

“This has been an extremely effective partnership and collaboration between the U, ARUP and Techcyte, demonstrating how university technology can be fast-tracked by collaborating with the right partners,” said Aaron Duffy, technology manager at the U’s Partners for Innovation, Ventures, Outreach & Technology (PIVOT) Center. PIVOT Center, which manages the U’s innovations and drives them to market, is now seeking partners to launch Nanospot.AI.

For more information, contact Duffy at PIVOT Center (aaron.duffy@utah.edu); Astill at ARUP (astillme@aruplab.com); or Cahoon at Techcyte (ben.cahoon@techcyte.com).

About PIVOT Center 
The Partners for Innovation, Ventures, Outreach & Technology (PIVOT) Center leads the University of Utah’s centralized and integrated strategy and operation for technology commercialization, corporate engagement, and economic development. In doing so, PIVOT Center serves as a hub for the U to foster partnerships between industry, university, and government entities. The center formalizes the U’s commitment to broaden its impact on Utah’s economy by enhancing local and global collaborations to catalyze innovation. The center’s mission is to generate economic returns for the university and the state of Utah, expand the university’s reputation for innovation, and positively impact society. The University of Utah was recently ranked second among large research universities for “innovation productivity impact.” 

About ARUP Laboratories
Founded in 1984, ARUP Laboratories is a leading national reference laboratory and a wholly-owned nonprofit enterprise of the University of Utah and its Department of Pathology. ARUP offers more than 3,000 tests and test combinations, ranging from routine screening tests to esoteric molecular and genetic assays. ARUP serves clients across the United States, including many of the nation’s top university teaching hospitals and children’s hospitals, as well as multihospital groups, major commercial laboratories, group purchasing organizations, military and other government facilities, and major clinics. In addition, ARUP is a worldwide leader in innovative laboratory research and development, led by the efforts of the ARUP Institute for Clinical and Experimental Pathology®. ARUP is ISO 15189 CAP accredited.

About Techcyte
Headquartered in Orem, Utah, Techcyte Inc. is the world leader in AI-based digital diagnostics for liquids and cells. Techcyte’s use of deep machine learning to perform automated analysis of both cellphone and microscopy images is revolutionizing human, animal and environmental diagnostics.

COVID-19 vaccines as effective in real-world settings as in clinical trials

mRNA COVID-19 vaccines offer substantial protection from infection by the novel coronavirus, SARS-CoV-2, in the “real-world”, concludes a large study carried out at six regions across the U.S. including Salt Lake City, Utah. The performance of the vaccines was consistent with their performance in closely controlled clinical trials that led to their approval for emergency use.

The results are particularly noteworthy considering that participants in the study were amongst those at highest-risk for being exposed to the virus, the researchers say. These included health care workers, first responders and essential workers who routinely come in close contact with the public as a routine part of their job.

“There are usually differences in how well interventions perform in clinical trials as compared to real-world settings,” explains Sarang Yoon, assistant professor at the University of Utah Rocky Mountain Center for Occupational and Environmental Health (RMCOEH) and principal investigator of the RECOVER (Research on the Epidemiology of SARS-CoV-2 in Essential Response Personnel) study in Utah. In this case, the results support a large body of evidence, from clinical trials and other research, showing that COVID-19 vaccines are very safe and effective.

“This research is showing how well these vaccines work,” says Yoon.

Headshot of Sarang Yang.

Sarang Yoon, assistant professor at the University of Utah Rocky Mountain Center for Occupational and Environmental Health and principal investigator of the RECOVER (Research on the Epidemiology of SARS-CoV-2 in Essential Response Personnel) study in Utah.

The study published on March 29 in the Morbidity Mortality Weekly Report (MMWR) from the Centers for Disease Control and Prevention. Kurt Hegmann, director of RMCOEH, Matthew Thiese, associate professor and Andrew Phillips, assistant professor of RMCOEH were co-investigators on the Utah study. Additional study sites that are part of the HEROES-RECOVER network are Phoenix and Tucson, Arizona; Portland, Oregon; Duluth, Minnesota; and Temple, Texas.

The study showed the mRNA COVID-19 vaccines were:

  • 90% effective at reducing risk for infection once participants were “fully” vaccinated, two weeks after the second dose.
  • 80% effective at reducing risk for infection after “partial” vaccination, two weeks after the first dose (before the second dose was given).

Among those fully vaccinated, there were only 3 infections among 2,479 workers and no severe COVID-19 infections or deaths in people who were vaccinated. This is much lower when compared to the period when participants were not immunized, 161 infections were identified.

The authors note that even though the vaccines were highly effective after one dose, it is not known how long that immunity lasts. The CDC recommends two doses of the Pfizer-BioNTech and Moderna vaccines.

3,950 study participants submitted samples for COVID-19 tests on a weekly basis for 13 weeks between December 14, 2020 to March 13, 2021. During that time, 2,479 participants have been fully vaccinated, receiving two doses of either the Pfizer-BioNTech or Moderna mRNA COVID-19 vaccine. In addition to submitting samples for COVID-19 test, participants reported weekly whether they had COVID-like symptoms including fever, shortness of breath and loss of taste or smell.

Study participants were:

  • Health care workers (e.g. physicians, nurses, medical assistants),
  • First responders (e.g. firefighters, police officers, staff at correctional facilities), and
  • Frontline and essential workers (e.g. teachers, hospitality, retail, restaurants, airlines).

Results from COVID-19 tests and surveys also showed that among those who tested positive for SARS-CoV-2, 87.3% had COVID-19 symptoms and 10.7% were asymptomatic.

“We are incredibly grateful to our participants for their time and dedication to the study.” says Yoon. “With their help, we will be able to better understand COVID-19 vaccine efficacy and COVID-19 illness.”

The RECOVER study is ongoing and results from future phases will help determine how long COVID-19 vaccines protect against infection and the real-world effectiveness of newer vaccines.

The research will also investigate how well COVID-19 vaccines protect against new variants of the SARS-CoV-2 virus that are highly transmissible and are now circulating in the U.S.

# # #

The research publishes as, “Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection among Healthcare Personnel, First Responders, and Other Essential and Frontline Workers – Six U.S. Region, December 2020-March 2021.”

U OF U Health research plays major role in new CDC guidelines

Research from University of Utah’s Health and Economic Recovery Outreach (HERO) Project contributed to the Centers for Disease Control and Prevention’s (CDC) revised physical distancing guidelines that reduces the space between students in classrooms from six feet to three feet.

Utah HERO partnered with Granite School District within Salt Lake County to investigate how COVID-19 spreads in elementary schools. The study found low levels of COVID-19 transmission when students and staff wore masks and followed other prevention measures, even when students were unable to be spaced six feet apart and when community infection rates were high.

The study took place in 20 elementary schools in the Granite School District and one independent school in Salt Lake City. To determine whether a positive case was acquired in school or out of school, researchers gathered detailed histories about the positive patient, and tested their initial contacts and household members. Overall, researchers found five secondary cases that were likely due to school exposure for a rate of 7 per 1,000 contacts.

“In four or five of these cases, there were obvious breakdowns in prevention strategies, including poor mask use,” says Adam Hersh, lead study investigator and professor in the Division of Pediatric Infectious Diseases at U of U Health. “This helped us understand why transmission happened in these instances.” Researchers also found in most positive cases, transmission was more likely among members of their households than between two masked students.

Although the study looked at the risk of infection from COVID-19 in one school district, researchers say the information can be related to classrooms in any part of the country if masking and other prevention measures are in place. “In-person schooling can be done safely with multi-layer, strictly enforced prevention measures,” says Andy Pavia, chief of the Division of Pediatric Infectious Diseases at U of U Health. “It enforces and reinforces the Governor’s recommendation that we should continue masking throughout all schools in Utah and provides reassurance that we know how to keep schools safe.”

The study did not look at COVID-19 transmission out of the classroom. “When masks are on, three feet of distance between students seems to be safe,” says Hersh. “However, in circumstances where masks are off, such as lunch, it’s really important to ensure there is more spacing than three feet.” At the time of the study, extracurricular school activities were limited. Researchers say COVID-19 transmission may look very different when students are playing sports and doing other activities where the environment is not as controlled.

The study validates that COVID-19 prevention measures are working and that in-person learning can be done safely under these conditions. “We hope this provides reassurance for our school communities throughout the state and for other communities throughout the county, many of which are struggling with decisions around school opening and school operations,” says Hersh.

Statement from the CDC Morbidity and Mortality Weekly Report (MMWR):

The study from Utah published in the MMWR presented findings supportive of CDC’s revised guidance allowing for three feet of distance between children in school settings. The Utah study, one of many across the nation, affirmed CDC’s recommendation that schools should return to in-person learning and that doing so can be accomplished safely for the protection of students, teachers and communities.  

“Based on available science, like the joint publication today by CDC and University of Utah, schools remain a safe place for America’s students and teachers when following CDC’s guidance,” said Victoria Chu, MD, MPH and author of MMWR article published today. “CDC remains committed to ensuring America’s children can return to in-person schooling for their well-being and development.”

University of Utah embarks on ambitious COVID-19 testing effort

The David Eccles School of Business at the University of Utah and University of Utah Health announce the start of Utah HERO (Health & Economic Recovery Outreach), a massive undertaking that will begin with the testing of 10,000 Utahns across four counties. The data gathered will inform decision-makers in the state as they work to help keep residents safe and get people back to work.

As part of Utah HERO, households in Utah, Davis, Salt Lake and Summit counties will be randomly selected for participation in the study. Random sampling is a way to accurately determine how much COVID-19 has spread in Utah without testing every person in the state.

Utah HERO team members will tag these households with a flyer or door hanger explaining the project. Field teams will then follow up with an in-person visit to gather information about those living in the residence and provide instruction on how to get tested. All those living in the residence who are 12 years and older will be asked to visit a testing site where they will receive two tests: PCR (swab test to detect the presence of coronavirus) and serology (blood draw to detect antibodies). Antibodies to the coronavirus indicate probable past infection.

“A survey of this magnitude would normally take months to organize, but we’ve been able to move things forward in a couple of weeks thanks to all of our collaborators,” said Stephen Alder, director of field operations for Utah HERO and professor in the Department of Family and Preventative Medicine. “The University of Utah is committed to serving the state during this difficult time and we hope this information will help our leaders make informed public health and business decisions.”

High levels of voluntary participation will enhance the accuracy of the study and will improve the ability to interpret results of COVID-19 testing. Testing is completely confidential and no information on immigration status will be collected.

U of U Health’s Wellness Bus and Huntsman Cancer Institute’s Cancer Screening bus—both of which have been redeployed to perform COVID-19 testing—will be set up in designated neighborhoods to serve as Utah HERO test sites. Testing will also take place at existing U of U Health evaluation tents, as well as pop-up locations at various church parking lots. Testing will be performed at ARUP Laboratories, which does all COVID-19 testing for U of U Health along with other clients in Utah and nationwide.

Utah HERO data will be used to more accurately establish the rate of infection in Utah and rates of infection in various age groups and job categories. The data are important because they will indicate where COVID-19 has spread, which occupations and other groups are most impacted and how many undetected infections are occurring. Undetected infections can occur because people have mild symptoms or no symptoms, or because of differences in testing. This can inform the safest way to relax public health restrictions and get Utah back to work.

“Utah HERO represents the critical balance between protecting public health and moving the economy forward,” said Taylor Randall, dean of the David Eccles School of Business. “This information will help us better understand how COVID-19 has spread through our community and inform business leaders on the best, data-driven ways to get people back into the workforce safely.”

The Governor’s Office of Management and Budget contracted with the U to design and implement Utah HERO. “This study is important because it is the first initiative to gain an understanding of statewide COVID-19 prevalence in Utah,” said Angela Dunn, state epidemiologist for the Utah Department of Health. “This random sampling allows us to see a representative picture of the extent to which COVID-19 has spread in our community. This will enable us to make informed decisions about how to best move forward,” she said.

Other Utah HERO collaborators include:

  • ARUP
  • Utah Department of Health
  • Salt Lake County Health Department
  • Summit County Health Department
  • Davis County Health Department
  • Utah County Health Department

Staffing for Utah HERO field teams is made possible by Hope Corps, a nonprofit organization that connects students to opportunities to serve in the state of Utah and help support the economy.

Here are a few additional details about Utah HERO:

  • The project will begin sampling small numbers of households then scale up over a period of weeks.
  • Survey participants do not pay for testing and do not need to show proof of insurance.
  • Survey participants do not need to show ID or proof of residency.
  • Those reporting symptoms will be instructed on safe practices to prevent the spread of COVID-19.
  • Those with positive test results will be notified and given instructions on how to quarantine and prevent the spread of the disease within households.
  • The Church of Jesus Christ of Latter-day Saints has generously provided parking lot space for additional testing sites.

For more information visit eccles.link/utahhero

ARUP/U of U Health find self-collected saliva, deep nasal swabs are equally effective for diagnosing COVID-19

Self-collected saliva and deep nasal swabs collected by healthcare providers are equally effective for detecting SARS-CoV-2, the virus that causes COVID-19, according to a new study conducted by ARUP Laboratories and University of Utah (U of U) Health.

The study, published in the Journal of Clinical Microbiology, represents one of the largest prospective specimen type comparisons to date, said Julio Delgado, ARUP chief medical officer. Other studies, including one from the Yale School of Public Health, have reached similar conclusions but with markedly fewer patients and specimens.

Researchers also found that specimens self-collected from the front of the nose are less effective than deep nasal swabs for virus detection. This finding prompted a subsequent study that has not yet been published in which researchers learned they could improve the sensitivity of anterior nasal swab testing to 98% by combining an anterior nasal swab with a swab collected from the back of the throat.

The results have important implications for patients and providers. The collection process for saliva and anterior nasal specimens is less invasive than the deep nasal, or nasopharyngeal, swab. In addition, both specimen types can be self-collected, reducing the risk of exposure for healthcare workers who collect nasopharyngeal specimens, said Kimberly Hanson, section chief of clinical microbiology at ARUP and the primary author of the study.

“Saliva and nasal swab self-collection can resolve many of the resource and safety issues involved in SARS-CoV-2 diagnostic testing,” Delgado said.

ARUP and U of U Health anticipate being able to start offering testing on saliva in some U of U Health clinical settings in early September. They already are using anterior nasal swabs in combination with throat swabs to test some asymptomatic individuals.

COVID-19 testing on these alternatives to nasopharyngeal swabs will increase with time, Delgado said. “From the start of the COVID-19 pandemic, ARUP has worked to build capacity for high-quality COVID-19 testing,” he said. “Our goal is to make this testing available to hospitals and healthcare systems nationwide.”

Hanson and her colleagues analyzed more than 1,100 specimens from 368 volunteers at the U of U Health Redwood Health Center drive-through testing site from late May through June. Volunteers self-collected saliva that they spit into a tube and swabbed from the front of both nostrils to produce specimens for testing. The researchers compared test results from these specimen types with test results from nasopharyngeal swabs healthcare providers collected from the volunteers. Discrepant results across specimens collected from the same patient triggered repeat testing using a second polymerase chain reaction (PCR)-based platform.

The study showed that SARS-CoV-2 was detected in at least two specimen types in 90% of the patients who tested positive for the virus.

As a standalone alternative specimen to nasopharyngeal swabs, saliva proved to be an excellent option, Hanson said. Positivity rates for saliva specimens were nearly the same as those for nasopharyngeal specimens.

The research showed that self-collected nasal swabs, when used alone, can miss nearly 15% of infections, which prompted researchers’ further study combining them with oropharyngeal, or throat swabs.

The research is an example of how ARUP and U of U Health continue to explore new methods to serve patients and the community as well as keep healthcare workers safe, said Richard Orlandi, chief medical officer for ambulatory health at U of U Health. “We appreciate the researchers at ARUP, as well as the staff and patients at our Redwood testing center who have participated in this discovery,” he said. “This exciting advance reflects ARUP’s and U of U Health’s innovative spirit and the benefits of our partnership.”

About ARUP Laboratories

Founded in 1984, ARUP Laboratories is a leading national reference laboratory and a nonprofit enterprise of the University of Utah and its Department of Pathology. ARUP offers more than 3,000 tests and test combinations, ranging from routine screening tests to esoteric molecular and genetic assays. ARUP serves clients across the United States, including many of the nation’s top university teaching hospitals and children’s hospitals, as well as multihospital groups, major commercial laboratories, group purchasing organizations, military and other government facilities, and major clinics. In addition, ARUP is a worldwide leader in innovative laboratory research and development, led by the efforts of the ARUP Institute for Clinical and Experimental Pathology®. ARUP is ISO 15189 CAP accredited.

See original post here.

SCALE-UP Utah awarded $5 million to improve COVID-19 testing among underserved and vulnerable populations

Across the US, COVID-19 is hitting some communities harder than others, and Utah is no exception. In our state, Latinos make up 14 percent of the population but represent 40 percent of cases. Similarly, there are disproportionately high case and death rates among Pacific Islanders, African-Americans, Native Americans, and Utahns living in low-income neighborhoods.

With a goal of reducing health disparities in Utah, the National Institutes of Health (NIH) has awarded $5 million to Rachel Hess, and Guilherme Del Fiol of University of Utah Health, and David Wetter of Huntsman Cancer Institute and U of U Health. The team leads SCALE-UP Utah, an initiative that aims to increase the acceptance, reach, uptake, and long-term sustainability of COVID-19 screening and testing. The initiative will be carried out in partnership with 12 community health center systems across the state that run 39 primary care clinics serving more than 115,000 patients—most of whom live in rural and underserved communities.

“SCALE-UP Utah brings together partners from across Utah to ensure that there is adequate screening and testing for all population groups with a specific emphasis on those experiencing higher rates of COVID-19 infection,” Wetter says. “No one should be left behind in being protected from COVID-19.”

U of U Health is one of 32 institutions that received an NIH award through the Rapid Acceleration of Diagnostics-Underserved Populations (RADx-UP) initiative. The program supports both projects designed to rapidly implement COVID-19 testing strategies in populations disproportionately affected by the pandemic and research that aims to better understand COVID-19 testing patterns among these populations.

“It is critical that all Americans have access to rapid, accurate diagnostics for COVID-19, especially underserved and vulnerable populations who are bearing the brunt of this disease,” says Francis S. Collins, director of NIH. “The RADx-UP program will help us better understand and alleviate the barriers to testing for those most vulnerable and reduce the burden of this disease.”

SCALE-UP Utah takes advantage of pre-existing, evidence-based interventions developed by the team at the Center for Health Outcomes and Population Equity (HOPE), led by Wetter at Huntsman Cancer Institute and the Center for Clinical and Translational Science at U of U Health. These include:

  • Initiating text messaging dialogues about testing and testing logistics between health care providers and patients who are at high risk for infection or severe disease.
  • Designing information technology tools that prompt health care providers to ask, advise, and connect patients to COVID-19 screening and testing.
  • Engaging patient navigators to motivate patients and address logistics and barriers that could otherwise prevent them from being tested for COVID-19.

The program is designed to roll out quickly and adapt as needed in order to reduce COVID-19-related health inequities. Wetter says an important goal of SCALE-UP Utah is to serve as a model for other health care systems that serve vulnerable and underserved populations.

Long-standing partnerships between the Center for Clinical and Translational Science, Huntsman Cancer Institute, Association for Utah Community Health, statewide community health centers, and the Utah Department of Health provide additional infrastructure and resources that will improve the reach of COVID-19 screening and testing.

In the future, the program can be readily adjusted and redeployed to meet additional health needs that arise during the pandemic. “SCALE-UP Utah will build an infrastructure that can be used for equitable dissemination of a COVID-19 vaccine once it becomes available,” Wetter says.

See original post here.

# # #

About Huntsman Cancer Institute at the University of Utah

Huntsman Cancer Institute (HCI) at the University of Utah is the official cancer center of Utah. The cancer campus includes a state-of-the-art cancer specialty hospital as well as two buildings dedicated to cancer research. HCI treats patients with all forms of cancer and is recognized among the best cancer hospitals in the country by U.S. News and World Report. As the only National Cancer Institute (NCI)-Designated Comprehensive Cancer Center in the Mountain West, HCI serves the largest geographic region in the country, drawing patients from Utah, Nevada, Idaho, Wyoming, and Montana. More genes for inherited cancers have been discovered at HCI than at any other cancer center in the world, including genes responsible for hereditary breast, ovarian, colon, head, and neck cancers, along with melanoma. HCI manages the Utah Population Database, the largest genetic database in the world, with information on more than 11 million people linked to genealogies, health records, and vital statistics. HCI was founded by Jon M. and Karen Huntsman.

About University of Utah Health

University of Utah Health is the state’s only academic health care system, providing leading-edge and compassionate care for a referral area that encompasses 10 percent of the US, including Idaho, Wyoming, Montana, and much of Nevada. A hub for health sciences research and education in the region, U of U Health touts a $408 million research enterprise and trains the majority of Utah’s physicians, including more than 1,460 health care providers each year at its Colleges of Health, Nursing, and Pharmacy and Schools of Dentistry and Medicine. With more than 20,000 employees, the system includes 12 community clinics and five hospitals: University Hospital, Huntsman Mental Health Institute, Huntsman Cancer Hospital, University Orthopaedic Center, and the Craig H. Neilsen Rehabilitation Hospital. For 11 straight years, U of U Health has ranked among the top 10 US academic medical centers in the rigorous Vizient Quality and Accountability Study.

COVID-19 causes ‘hyperactivity’ in blood-clotting cells

Changes in blood platelets triggered by COVID-19 could contribute to the onset of heart attacks, strokes and other serious complications in some patients who have the disease, according to University of Utah Health scientists. The researchers found that inflammatory proteins produced during infection significantly alter the function of platelets, making them “hyperactive” and more prone to form dangerous and potentially deadly blood clots.

They say better understanding the underlying causes of these changes could possibly lead to treatments that prevent them from happening in COVID-19 patients. Their report appears in Blood, an American Society of Hematology journal.

“Our finding adds an important piece to the jigsaw puzzle that we call COVID-19,” says Robert A. Campbell, senior author of the study and an assistant professor in the Department of Internal Medicine. “We found that inflammation and systemic changes, due to the infection, are influencing how platelets function, leading them to aggregate faster, which could explain why we are seeing increased numbers of blood clots in COVID patients.”

Headshot of a man with blonde hair in white button shirt, yellow wearing glasses.

Depiction of a blood clot forming inside a blood vessel. 3D illustration

Emerging evidence suggests COVID-19 is associated with an increased risk of blood clotting, which can lead to cardiovascular problems and organ failure in some patients, particularly among those with underlying medical problems such as diabetes, obesity or high blood pressure.

To find out what might be going on, the researchers studied 41 COVID-19 patients hospitalized at University of Utah Hospital in Salt Lake City. Seventeen of these patients were in the ICU, including nine who were on ventilators. They compared blood from these patients with samples taken from healthy individuals who were matched for age and sex.

Using differential gene analysis, the researchers found that SARS-CoV-2, the virus that causes COVID-19, appears to trigger genetic changes in platelets. In laboratory studies, they studied platelet aggregation, an important component of blood clot formation, and observed COVID-19 platelets aggregated more readily. They also noted that these changes significantly altered how platelets interacted with the immune system, likely contributing to inflammation of the respiratory tract that may, in turn, result in more severe lung injury.

Surprisingly, Campbell and his colleagues didn’t detect evidence of the virus in the vast majority of platelets, suggesting that it could be promoting the genetic changes within these cells indirectly.

One possible mechanism is inflammation, according to Bhanu Kanth Manne, one of the study’s lead authors and a research associate with the University of Utah Molecular Medicine Program (U2M2). In theory, inflammation caused by COVID-19 could affect megakaryocytes, the cells that produce platelets. As a result, critical genetic alterations are passed down from megakaryocytes to the platelets, which, in turn, make them hyperactive.

In test-tube studies, the researchers found that pre-treating platelets from SARS-CoV-2 infected patients with aspirin did prevent this hyperactivity. These findings suggest aspirin may improve outcomes; however, this will need further study in clinical trials. For now, Campbell warns against using aspirin to treat COVID-19 unless recommended by your physician.

In the meantime, the researchers are beginning to look for other possible treatments.

“There are genetic processes that we can target that would prevent platelets from being changed,” Campbell says. “If we can figure out how COVID-19 is interacting with megakaryocytes or platelets, then we might be able to block that interaction and reduce someone’s risk of developing a blood clot.”

Find original post here.


This study titled, “Platelet Gene Expression and Function in COVID-19 Patients,” was funded by the National Institutes of Health, the University of Utah Health 3i Initiative and the American Heart Foundation.

SARS-CoV-2-like particles very sensitive to temperature

Winter is coming in the northern hemisphere and public health officials are asking how the seasonal shift will impact the spread of SARS-CoV-2, the virus that causes COVID-19?

A new study tested how temperatures and humidity affect the structure of individual SARS-Cov-2 virus-like particles on surfaces. They found that just moderate temperature increases broke down the virus’ structure, while humidity had very little impact. In order to remain infectious, the SARS-Cov-2 membrane needs a specific web of proteins arranged in a particular order. When that structure falls apart, it becomes less infectious. The findings suggest that as temperatures begin to drop, particles on surfaces will remain infectious longer.

This is the first study to analyze the mechanics of the virus on an individual particle level, but the findings agree with large-scale observations of other coronaviruses that appear to infect more people during the winter months.

“You would expect that temperature makes a huge difference, and that’s what we saw. To the point where the packaging of the virus was completely destroyed by even moderate temperature increases,” said Michael Vershinin, assistant professor in the Department of Physics & Astronomy at the University of Utah and co-senior author of the paper. “What’s surprising is how little heat was needed to break them down—surfaces that are warm to the touch, but not hot. The packaging of this virus is very sensitive to temperature.

The paper published online on Nov. 28, 2020, in the journal Biochemical Biophysical Research Communications. The team also published a separate paper on Dec. 14, 2020, in Scientific Reportsdescribing their method for making the individual particle packaging. The virus-like particles are empty shells made from the same lipids and three types of proteins as are on active SARS-Cov-2 viruses, but without the RNA that causes infections. This new method allows scientists to experiment with the virus without risking an outbreak.

The SARS-CoV-2 is commonly spread by exhaling sharply, (e.g. sneezing or coughing), which ejects droplets of tiny aerosols from the lungs. These mucus-y droplets have a high surface to volume ratio and dry out quickly, so both wet and dry virus particles come into contact with a surface or travel directly into a new host. The researchers mimicked these conditions in their experiments.

They tested the virus-like particles on glass surfaces under both dry and humid conditions. Using atomic force microscopy they observed how, if at all, the structures changed. The scientists exposed samples to various temperatures under two conditions: with the particles inside a liquid buffer solution, and with the particles dried out in the open. In both liquid and bare conditions, elevating the temperature to about 93 degrees F for 30 minutes degraded the outer structure. The effect was stronger on the dry particles than on the liquid-protected ones. In contrast, surfaces at about 71 degrees F caused little to no damage, suggesting that particles in room temperature conditions or outside in cooler weather will remain infectious longer.

They saw very little difference under levels of humidity on surfaces, however, the scientists stress that humidity likely does matter when the particles are in the air by affecting how fast the aerosols dry out. The research team is continuing to study the molecular details of virus-like particle degradation.

“When it comes to fighting the spread of this virus, you kind of have to fight every particle individually. And so you need to understand what makes each individual particle degrade,” Vershinin said. “People are also working on vaccines and are trying to understand how the virus is recognized? All of these questions are single-particle questions. And if you understand that, then that enables you to fight a hoard of them.”

Abhimanyu Sharma, Benjamin Preece, Heather Swann, and Saveez Saffarian of the University of Utah and Xiangyu Fan, Richard .J. McKenney and Kassandra M. Ori-McKenney of University of California, Davis were also authors of the Biochem Biophys Res Comms study. Heather Swann,  Abhimanyu Sharma, Benjamin Preece, Abby Peterson, Crystal Eldridge, David M. Belnap and Saveez Saffarian of the University of Utah also co-authored the Scientific Reports study.

Find the original post here.

Portable, reusable test for COVID-19

“Testing, testing, testing.” It’s a mantra that health officials have been constantly promoting because screening people for COVID-19 is the best way to contain its spread. In the U.S., however, that crucial necessity has been hampered due to a lack of supplies.

But University of Utah electrical and computer engineering professor Massood Tabib-Azar has received a $200,000 National Science Foundation Rapid Response Research (RAPID) grant to develop a portable, reusable coronavirus sensor that people can always carry with them. The sensor, about the size of a quarter, works with a cellphone and can detect COVID-19 in just 60 seconds.

“It can be made to be a standalone device, but it can also be connected to a cellphone,” says Tabib-Azar. “Once you have it connected either wirelessly or directly, you can use the cellphone software and processor to give a warning if you have the virus.”

Health officials say the U.S. needs to conduct at least five million COVID-19 tests per day to effectively understand and contain the spread of the virus. But at most, 319,000 per day have been given, according to The COVID Tracking Project, mostly due to a lack of testing supplies such as swabs and reagents. Typically, a 6-inch swab is inserted through the nose to the back of the cavity for 15 seconds to obtain a sample that is sent to a lab for analysis. Most tests take between four to seven days for the results.

A headshot of an engineer standing in front of technological equipment, in a brown jacket, red tie, blue shirt, wearing glasses.

University of Utah electrical and computer engineering professor Massood Tabib-Azar.

Tabib-Azar’s technology, which was profiled in two papers published last month in IEEE Sensors Journal, involves just a drop of saliva and can produce results in a minute. It is based on a sensor Tabib-Azar first began developing for the NSF about a year ago to detect the Zika virus. He is now converting the same technology to work with COVID-19.

The sensor would use single-strand DNA called aptamers in the sensor that would attach to the proteins in the COVID-19 virus molecule if it is present. A person would plug the small sensor into the cellphone’s power jack and launch an app made for the device. To test for the presence of the virus, the user would place a drop of saliva on the sensor, and the results would appear on the phone. It is designed to also test for the virus on the surface of something, like a table or desk, by brushing a swab on the surface and then on the sensor. And it might be able to detect the presence of COVID-19 in floating microscopic particles in the air in enclosed spaces such as an elevator (while the virus is currently considered not airborne, studies are being conducted to determine if minute particles of the virus can hang in floating droplets in the air.).

If the virus is present, the DNA strands in the sensor would bind to the virus’ proteins and electrical resistance is measured in the device, signaling a positive result.

Tabib-Azar says the sensor would include an array of tiny devices inside it, each with a DNA strand that looks for a different protein. A specific combination of proteins would be unique to just COVID-19.

“By increasing the number of devices and single-strand DNA, we can increase the sensor’s accuracy and reduce the false positives and false negatives,” he says.

The sensor is designed to be reusable because it can destroy the previous sample on it by producing a small electrical current that could heat up and remove or disintegrate the virus. Tabib-Azar says the entire process would use little battery power from the cellphone.

Another possible method would involve putting the saliva sample on disposable sheets that are placed on top of the sensor like a sticky note. This would decrease cross-contamination on the sensor and eliminate the need to heat up and destroy the sample afterward.

The device also can be designed to upload the results to a central server that maps out positive results in an area, giving researchers a clearer and more accurate picture of where hotspots are with big outbreaks of the virus.

Because Tabib-Azar has already developed the technology—and a prototype—to detect the Zika virus, he said he could have a prototype of the new COVID-19 sensor for clinical trials in two to three months.